The opening of Telomir Pharma's shares at the IPO price indicates a neutral market reception initially. This neutral start suggests that the market had accurately priced the shares for the IPO, reflecting a balanced view on the company's valuation and prospects at the time of listing. However, investor sentiment and market dynamics could influence future price movements.